All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis probably leads to lower pulmonary embolism compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in symptomatic deep vein thrombosis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in minor bleeding compared with no prophylaxis (low certainty).
1 finding from 1 review
Mortality at 6 months: main analysis · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality at 6 months: main analysis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes pulmonary embolism compared with no prophylaxis (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes symptomatic deep vein thrombosis compared with no prophylaxis (very low certainty).
1 finding from 1 review
Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher minor bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Quality of life ‐ not reported · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people undergoing elective pancreatic resections
Drain use showed no clear difference in mortality compared with no drain use following pancreatic surgery (low certainty).
2 findings from 1 review
Intra‐abdominal infection · people undergoing elective pancreatic resections
It is very uncertain whether active drain changes intra‐abdominal infection compared with passive drain following pancreatic surgery (very low certainty).
1 finding from 1 review
Wound infection · people undergoing elective pancreatic resections
It is very uncertain whether active drain changes wound infection compared with passive drain following pancreatic surgery (very low certainty).
1 finding from 1 review
Drain‐related complications · people undergoing elective pancreatic resections
1 finding from 1 review
Morbidity · people undergoing elective pancreatic resections
It is very uncertain whether active drain changes morbidity compared with passive drain following pancreatic surgery (very low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing elective pancreatic resections
It is very uncertain whether active drain changes length of hospital stay compared with passive drain following pancreatic surgery (very low certainty).
1 finding from 1 review
All‐cause mortality · people undergoing elective pancreatic resections
It is very uncertain whether early changes mortality compared with late drain removal following pancreatic surgery (very low certainty).
2 findings from 1 review